Diffuse Large B-cell Lymphoma, Lymphoma, Non-Hodgkin Lymphoma
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
A051701 is temporarily closed to accrual effective August 2, 2021.
A051701 accrual of patients with double expressing lymphoma (DEL) is temporarily halted effective August 2, 2021.
A051701 accrual of patients of all ages with double hit lymphoma (DHL) is temporarily halted effective September 28, 2020.